Towards reproducible research in recurrent pregnancy loss immunology: Learning from cancer microenvironment deconvolution.
RPL
bioinformatics
cancer microenvironment
reproductive immunology
transcriptomics
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
10
2022
accepted:
13
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
The most recent international guidelines regarding recurrent pregnancy loss (RPL) exclude most of the immunological tests recommended for RPL since they do not reach an evidence-based level. Comparisons for metanalysis and systematic reviews are limited by the ambiguity in terms of RPL definition, etiological and risk factors, diagnostic work-up, and treatments applied. Therefore, cohort heterogeneity, the inadequacy of numerosity, and the quality of data confirm a not standardized research quality in the RPL field, especially for immunological background, for which potential research application remains confined in a separate single biological layer. Innovative sequencing technologies and databases have proved to play a significant role in the exploration and validation of cancer research in the context of dataset quality and bioinformatics tools. In this article, we will investigate how bioinformatics tools born for large-scale cancer immunological research could revolutionize RPL immunological research but are limited by the nature of current RPL datasets.
Identifiants
pubmed: 36911667
doi: 10.3389/fimmu.2023.1082087
pmc: PMC9996132
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1082087Informations de copyright
Copyright © 2023 Betti, Vizza, Piccione, Pietropolli, Chiofalo, Pallocca and Bruno.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2020 May 14;10(1):7970
pubmed: 32409705
BMJ. 2020 Oct 7;371:m3502
pubmed: 33028606
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Fertil Steril. 2021 Mar;115(3):546-560
pubmed: 33581856
Commun Biol. 2020 Jan 21;3(1):37
pubmed: 31965050
J Formos Med Assoc. 2018 Mar;117(3):204-211
pubmed: 28465068
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Anal Chim Acta. 2021 Jan 2;1141:144-162
pubmed: 33248648
BMC Bioinformatics. 2007 Oct 25;8:412
pubmed: 17961233
J Clin Med. 2021 Feb 20;10(4):
pubmed: 33672505
PLoS One. 2008 Apr 30;3(4):e2078
pubmed: 18446208
Eur J Surg Oncol. 2020 Sep;46(9):1697-1702
pubmed: 32204935
Sci Rep. 2020 Aug 4;10(1):13088
pubmed: 32753622
Hum Reprod Update. 2019 Sep 11;25(5):564-591
pubmed: 31424502
Semin Reprod Med. 2007 Nov;25(6):445-53
pubmed: 17960529
Front Immunol. 2021 Jun 07;12:689019
pubmed: 34168655
Hum Reprod. 2016 May;31(5):1014-23
pubmed: 26965434
Front Immunol. 2014 Nov 24;5:606
pubmed: 25505471
Genomics Proteomics Bioinformatics. 2021 Apr;19(2):208-222
pubmed: 33482359
Am J Reprod Immunol. 2015 Aug;74(2):100-9
pubmed: 25582625
Mol Immunol. 2013 Aug;55(1):8-15
pubmed: 23062611
Front Oncol. 2020 Mar 12;10:156
pubmed: 32226771
Front Immunol. 2022 Apr 27;13:826198
pubmed: 35572542
Acta Obstet Gynecol Scand. 2018 Oct;97(10):1192-1199
pubmed: 29806956
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880
pubmed: 32274301
Trends Genet. 2006 Feb;22(2):101-9
pubmed: 16380191
Toxicol Pathol. 2014;42(2):327-38
pubmed: 23531796
Lancet. 2021 May 1;397(10285):1658-1667
pubmed: 33915094
Placenta. 2010 Mar;31 Suppl:S82-6
pubmed: 20106522
PLoS One. 2012;7(12):e52252
pubmed: 23300625
Int J Med Sci. 2022 Mar 6;19(3):546-562
pubmed: 35370464
J Reprod Immunol. 2011 Dec;92(1-2):97-102
pubmed: 22015003